
Ladislav Senolt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/239363/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology, 2022, 61, 1867-1876.	1.9	11
2	Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 612.	2.6	3
3	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. Frontiers in Immunology, 2022, 13, 811045.	4.8	2
4	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up Clinical and Experimental Rheumatology, 2022, , .	0.8	0
5	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. Frontiers in Medicine, 2022, 9, .	2.6	5
6	Interleukin-35 in idiopathic inflammatory myopathies. Cytokine, 2021, 137, 155350.	3.2	3
7	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	3.3	9,439
8	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. Scientific Reports, 2021, 11, 4719.	3.3	7
9	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. Scientific Reports, 2021, 11, 6063.	3.3	17
10	P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. Rheumatology, 2021, 60, .	1.9	3
11	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Rheumatology, 2021, 60, 5060-5072.	1.9	6
12	The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmunity Reviews, 2021, 20, 102797.	5.8	56
13	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	3.5	8
14	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	3.2	5
15	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. Scientific Reports, 2021, 11, 11525.	3.3	10
16	Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays. Scientific Reports, 2021, 11, 17300.	3.3	5
17	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. Biomarkers in Medicine, 2021, 15, 5-13.	1.4	3
18	IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. Frontiers in Immunology, 2021, 12, 745523.	4.8	11

#	Article	IF	CITATIONS
19	Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4. Frontiers in Immunology, 2021, 12, 716250.	4.8	16
20	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules, 2021, 11, 4.	4.0	5
21	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.8	1
22	Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. Current Opinion in Rheumatology, 2020, 32, 534-541.	4.3	16
23	Identification of Novel Native Autoantigens in Rheumatoid Arthritis. Biomedicines, 2020, 8, 141.	3.2	18
24	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. BMC Rheumatology, 2020, 4, 13.	1.6	1
25	MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction. Scientific Reports, 2020, 10, 5845.	3.3	21
26	Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients. Journal of Proteomics, 2019, 208, 103484.	2.4	16
27	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. Cytokine, 2019, 116, 13-20.	3.2	17
28	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International, 2019, 39, 1037-1043.	3.0	6
29	Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open, 2019, 9, e024713.	1.9	9
30	AB0687â€EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES – PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
31	FRI0107â€THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
32	OP0066â€EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WI SYSTEMIC SCLEROSIS – PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .	ſH	0
33	THU0062â€THE DYSREGULATION OF NK CELLS AND NON-CLASSICAL AND CLASSICAL MONOCYTE SUBPOPULATIONS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. , 2019, , .		Ο
34	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International, 2019, 39, 469-478.	3.0	23
35	Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Research, 2019, 8, 1549.	1.6	41
36	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clinical and Experimental Rheumatology, 2019, 37, 342-343.	0.8	8

#	Article	IF	CITATIONS
37	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.8	1
38	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clinical Rheumatology, 2018, 37, 2055-2062.	2.2	23
39	Biomarkers of hand osteoarthritis. Rheumatology International, 2018, 38, 725-735.	3.0	14
40	The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Frontiers in Immunology, 2018, 9, 2226.	4.8	51
41	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskeletal Disorders, 2018, 19, 264.	1.9	20
42	Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3. PLoS ONE, 2018, 13, e0203214.	2.5	27
43	The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2017, 76, 756-764.	0.9	53
44	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 79.	3.5	35
45	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nature Communications, 2017, 8, 1130.	12.8	245
46	08.48â€Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
47	08.49â€Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients – preliminary data from a single-centre controlled study. , 2017, , .		0
48	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. Cytokine, 2017, 97, 187-192.	3.2	10
49	Adipokines: role in local and systemic inflammation of rheumatic diseases. Expert Review of Clinical Immunology, 2017, 13, 1-3.	3.0	11
50	08.47â€Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
51	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS ONE, 2017, 12, e0185323.	2.5	30
52	02.30â€High levels of mir-451a differentiate patients with clinically suspect arthralgia from healthy controls. , 2017, , .		0
53	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017, 12, e0183420.	2.5	32
54	A3.10â€Serum calprotectinis elevated in patients with early rheumatoid arthritis but not in patients at risk of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A36.1-A36.	0.9	0

#	Article	IF	CITATIONS
55	SAT0466â€Progression of Pain and Ultrasound Detected Synovitis in Patients with Erosive Hand Osteoarthritis over One Year. Annals of the Rheumatic Diseases, 2016, 75, 839.3-840.	0.9	0
56	AB0952â€Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1227.1-1227.	0.9	0
57	A9.02â€Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2016, 75, A70.2-A71.	0.9	0
58	Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Research and Therapy, 2016, 18, 275.	3.5	40
59	Increased levels of peptidylarginine deiminase 2 in synovial fluid from anti-CCP-positive rheumatoid arthritis patients: Association with disease activity and inflammatory markers. Rheumatology, 2016, 55, 918-927.	1.9	42
60	A10.17â€Interleukin-20 serum levels correlate with disease activity in rheumatoid arthritis patients and decrease in response to rituximab treatment. Annals of the Rheumatic Diseases, 2016, 75, A79.2-A79.	0.9	0
61	THUO353â€Serum Tweak Levels in Patients with Neuropsychiatric Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 315.1-315.	0.9	0
62	SAT0068â€Circulating MIR-126 Is A Marker of Disease Activity in Patients with Early RA but Does Not Differentiate Patients at Risk of Developing RA. Annals of the Rheumatic Diseases, 2016, 75, 689.2-689.	0.9	0
63	AB0696â€Clinical Characteristics of Spondyloarthritis in The Czech Republic: A Single Centre Cohort. Annals of the Rheumatic Diseases, 2016, 75, 1142.2-1143.	0.9	0
64	A8.06â€Microrna-125b expression in PBMCS is inversely associated with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A67.1-A67.	0.9	0
65	AB0599â€Interleukin-35 in Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2016, 75, 1109.2-1109.	0.9	0
66	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 124.	3.5	48
67	Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.9	38
68	An update on biomarkers in axial spondyloarthritis. Autoimmunity Reviews, 2016, 15, 501-509.	5.8	58
69	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS ONE, 2016, 11, e0165498.	2.5	14
70	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Clinical and Experimental Rheumatology, 2016, 34, 222-9.	0.8	2
71	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. Arthritis Research and Therapy, 2015, 17, 341.	3.5	14
72	A6.26â€Analysis of circulating mirnas in patients with axial sponyloarthritis with different spinal involvement. Annals of the Rheumatic Diseases, 2015, 74, A66.1-A66.	0.9	1

#	Article	IF	CITATIONS
73	A3.10â€Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A35.1-A35.	0.9	1
74	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. Mediators of Inflammation, 2015, 2015, 1-6.	3.0	34
75	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 252.	3.5	60
76	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine, 2015, 73, 36-43.	3.2	44
77	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	1.9	17
78	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers, 2015, 20, 47-51.	1.9	12
79	Efficacy and Safety of Anti–Interleukinâ€⊋0 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Arthritis and Rheumatology, 2015, 67, 1438-1448.	5.6	39
80	S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.9	52
81	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0132674.	2.5	28
82	Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 489-496.	0.6	9
83	Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort. PLoS ONE, 2014, 9, e103495.	2.5	25
84	THU0168â€Monotherapy with Biological Disease-Modifying Anti-Rheumatic Drugs-Data from the Czech Registry Attra:. Annals of the Rheumatic Diseases, 2014, 73, 238.2-238.	0.9	0
85	THU0528â€Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 366.1-366.	0.9	1
86	A1.48â€Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A20.2-A21.	0.9	1
87	OP0240â€Signal Transducer and Activator of Transcription 3 Regulates Fibroblast Activation as A Downstream Mediator of Transforming Growth Factor-Beta. Annals of the Rheumatic Diseases, 2014, 73, 153.1-153.	0.9	Ο
88	AB0114â€Comparative Analysis of the Expression of Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) in Autoimmune Disease. Annals of the Rheumatic Diseases, 2014, 73, 841.3-842.	0.9	0
89	The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2014, 16, 468.	3.5	13
90	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1898-1904.	0.9	165

#	Article	IF	CITATIONS
91	A3.16â€Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, A48.1-A48.	0.9	1
92	AB0203â€S100A4 Serum Levels Correlate with Disease Activity, Skin Fibrosis and Lung Involvement in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 871.1-871.	0.9	1
93	SAT0205â€Potential of US 7 Score in Evaluating of Disease Activity of Patients with Rheumatoid Arthritis in the State of Remission. Annals of the Rheumatic Diseases, 2014, 73, 664.1-664.	0.9	Ο
94	Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen. Arthritis Research and Therapy, 2014, 16, 498.	3.5	68
95	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology, 2014, 53, 1520-1526.	1.9	72
96	Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?. BMC Medicine, 2014, 12, 49.	5.5	27
97	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Annals of the Rheumatic Diseases, 2014, 73, 1215-1222.	0.9	78
98	AB0163â€Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 856.4-857.	0.9	0
99	AB0818â€Bone Mineral Density and Metabolic Risk Factors in Patients with Non-Erosive and Erosive Hand Osteoarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1073.3-1074.	0.9	Ο
100	SAT0565â€The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA. Annals of the Rheumatic Diseases, 2014, 73, 795.1-795.	0.9	0
101	SAT0188â€Serum Calprotectin (S100A8/9) Correlates with Clinical and Ultrasound Outcomes in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 658.1-658.	0.9	Ο
102	Chronic repetitive nonprogressive epilepsia partialis continua due to rheumatoid meningitis. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 80-82.	2.0	16
103	The Role of Resistin in Inflammatory Myopathies. Current Rheumatology Reports, 2013, 15, 336.	4.7	15
104	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine, 2013, 64, 441-447.	3.2	19
105	A8.3â€Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.9	Ο
106	A7.3â€Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.3-A49.	0.9	0
107	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Annals of the Rheumatic Diseases, 2012, 71, 71-74.	0.9	55
108	Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A15.2-A15.	0.9	0

#	Article	IF	CITATIONS
109	Muscle and Fat Metabolism in Obesity After Kidney Transplantation: No Effect of Peritoneal Dialysis or Hemodialysis. , 2012, 22, 166-170.		10
110	MiRs in RA: possible biomarkers and therapeutic targets. Arthritis Research and Therapy, 2012, 14, .	3.5	1
111	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine, 2012, 58, 165-168.	3.2	29
112	Calprotectin (a S100 protein) as a sensitive biomarker for rheumatoid arthritis: new perspectives for an old finding. International Journal of Clinical Rheumatology, 2012, 7, 127-129.	0.3	1
113	Resistin in idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2012, 14, R111.	3.5	21
114	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clinical Rheumatology, 2012, 31, 67-71.	2.2	18
115	Pentosidine, an Advanced Glycation End-Product, May Reflect Clinical and Morphological Features of Hand Osteoarthritis. Open Rheumatology Journal, 2012, 6, 64-69.	0.2	6
116	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R122.	3.5	69
117	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine, 2011, 55, 116-121.	3.2	31
118	Adipokine profile is modulated in subcutaneous adipose tissue by TNFÂ inhibitors in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 2054-2056.	0.9	9
119	Modulation of subcutaneous adipose tissue adipokines by TNF-Â blockade therapy in patients with inflammatory arthritides. Annals of the Rheumatic Diseases, 2011, 70, A85-A85.	0.9	Ο
120	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. Rheumatology, 2011, 50, 1766-1772.	1.9	35
121	Potential role of S100A4 in an immune response of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A85-A85.	0.9	Ο
122	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. Immunology Letters, 2010, 128, 124-130.	2.5	35
123	Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4. Annals of the Rheumatic Diseases, 2010, 69, A38-A39.	0.9	Ο
124	Immune cell-derived microparticles in polymyositis/dermatomyositis. Annals of the Rheumatic Diseases, 2010, 69, A55-A56.	0.9	0
125	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1410-1411.	0.9	94
126	Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Annals of the Rheumatic Diseases, 2009, 68, 1285-1289.	0.9	59

#	Article	IF	CITATIONS
127	Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis: Figure 1. Annals of the Rheumatic Diseases, 2009, 68, 295-296.	0.9	112
128	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. Rheumatology, 2009, 48, 1590-1594.	1.9	40
129	Serum hyaluronic acid as a potential marker with a predictive value for further radiographic progression of hand osteoarthritis. Osteoarthritis and Cartilage, 2009, 17, 1615-1619.	1.3	39
130	Prospective new biological therapies for rheumatoid arthritis. Autoimmunity Reviews, 2009, 9, 102-107.	5.8	119
131	The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clinical Immunology, 2009, 133, 157-170.	3.2	345
132	The link between metastasis-associated protein S100A4 and rheumatoid arthritis. Joint Bone Spine, 2008, 75, 242-243.	1.6	1
133	The metastasis associated protein S100A4: a potential novel link to inflammation and consequent aggressive behaviour of rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases, 2008, 67, 1499-1504.	0.9	57
134	Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine, 2007, 38, 151-156.	3.2	140
135	Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: Putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 779-789.	6.7	91
136	Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine, 2006, 35, 247-252.	3.2	141
137	S100A4 (Mts1): Is there any relation to the pathogenesis of rheumatoid arthritis?. Autoimmunity Reviews, 2006, 5, 129-131.	5.8	30
138	S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Annals of the Rheumatic Diseases, 2006, 65, 1645-1648.	0.9	73
139	Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Annals of the Rheumatic Diseases, 2006, 66, 458-463.	0.9	226
140	Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Annals of the Rheumatic Diseases, 2005, 64, 886-890.	0.9	67
141	Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 277-283.	1.3	89
142	Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. Clinica Chimica Acta, 2003, 328, 59-69.	1.1	39
143	Title is missing!. Arthritis Research, 2003, 5, 167.	2.0	0
144	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.8	1